A NEW IDEA ON BIOTECH CYTK — GOOD TRIAL DATA — BUYOUT TARGET
By Nigam Arora & Dr. Natasha Arora CYTK is demonstrating good trial data in patients with obstructive hypertrophic cardiomyopathy. The data shows aficamten is superior to the current standard of care beta blockers. CYTK is a buyout target. To date, 205 Arora portfolio companies have been bought out. Producing a fortune for
May 13, 2025